LMP-420 Reduces HIV-1 and Mycobacterium tuberculosis Replication
Author Information
Author(s): Haraguchi Soichi, Day Noorbibi K, Kamchaisatian Wasu, Beigier-Pompadre Macarena, Stenger Steffen, Tangsinmankong Nutthapong, Sleasman John W, Pizzo Salvatore V, Cianciolo George J
Primary Institution: Department of Pediatrics, University of South Florida
Hypothesis
Can LMP-420, a small-molecule inhibitor of TNF-alpha, block the replication of HIV-1 and Mycobacterium tuberculosis?
Conclusion
LMP-420 effectively inhibits the replication of both HIV-1 and Mycobacterium tuberculosis in human cells.
Supporting Evidence
- LMP-420 alone inhibited HIV replication over 7 days with an IC50 of ~300 nM.
- Combination of LMP-420 with AZT doubled the level of HIV inhibition observed with AZT alone.
- LMP-420 alone inhibited the replication of virulent M. Tb by >80%.
Takeaway
LMP-420 is a new drug that helps stop two bad germs, HIV and tuberculosis, from making more copies of themselves in our bodies.
Methodology
LMP-420 was tested on HIV-1 infected human peripheral blood mononuclear cells and Mycobacterium tuberculosis-infected human alveolar macrophages to measure viral and bacterial replication.
Limitations
The study is limited to in vitro results and does not address potential clinical outcomes or long-term effects.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website